Journal Club #21 - Pharmacological and Behavioral Effects of Ibogaine in Substance Use Disorders: A Systematic Review of Animal and Human Studies
Sogol Fereydouni, MSc
Tuesday 3 February, 2026 8PM CET (7PM GMT, 2PM ET, 11AM PT)
Online via Zoom
Add to Calendar
February 3rd is drawing near, and we have something special lined up. This time, we’ll be discussing a systematic review on ibogaine and its effects on substance use disorders, presented by our volunteer social media contributor Sogol Fereydouni.
In her review, Sogol takes a closer look at recent in vivo animal models and human studies, offering a structured overview of the potential neurological pathways through which ibogaine and its congeners may exert their effects in individuals (and animals) with substance use disorders.
What makes this session particularly exciting is that the review is still a work in progress. While this means we won’t be able to share the paper in advance, it also gives attendees a rare opportunity to get a sneak peek at research as it’s actively taking shape. You can sit back, relax, and enjoy Sogol’s presentation while being right at the forefront of research in progress.
Preparation isn’t required, but for those interested in exploring the topic further, you’re welcome to dive deeper into ibogaine beforehand. We also recommend checking out our recorded conversation with Juliana Mulligan on ibogaine and the broader iboga landscape.
Ibogaine has been receiving increasing attention as a potential treatment for substance use disorders, with emerging interest in its possible applications for brain injury as well. Still, much remains unknown. Compared to more widely studied psychedelics, ibogaine research is relatively young, and rapidly evolving. Keeping track of new findings can be challenging, and this is exactly where Sogol’s systematic review comes in.
We look forward to having you join us for this engaging and timely discussion.
In her review, Sogol takes a closer look at recent in vivo animal models and human studies, offering a structured overview of the potential neurological pathways through which ibogaine and its congeners may exert their effects in individuals (and animals) with substance use disorders.
What makes this session particularly exciting is that the review is still a work in progress. While this means we won’t be able to share the paper in advance, it also gives attendees a rare opportunity to get a sneak peek at research as it’s actively taking shape. You can sit back, relax, and enjoy Sogol’s presentation while being right at the forefront of research in progress.
Preparation isn’t required, but for those interested in exploring the topic further, you’re welcome to dive deeper into ibogaine beforehand. We also recommend checking out our recorded conversation with Juliana Mulligan on ibogaine and the broader iboga landscape.
Ibogaine has been receiving increasing attention as a potential treatment for substance use disorders, with emerging interest in its possible applications for brain injury as well. Still, much remains unknown. Compared to more widely studied psychedelics, ibogaine research is relatively young, and rapidly evolving. Keeping track of new findings can be challenging, and this is exactly where Sogol’s systematic review comes in.
We look forward to having you join us for this engaging and timely discussion.
